Global Custom Market Research Reports Provider Company

phone

Colorectal Cancer - Pipeline Review, H2 2018

  • Published Date: 21 Dec 2018
  • Number of Pages: 2548
  • Category: Pharmaceuticals
  • Country: Global
Colorectal Cancer - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer - Pipeline Review, H2 2018, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.

Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason. Risk factors include smoking, heavy alcohol use, inflammatory bowel disease (IBD) and family history. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 28, 157, 178, 17, 204, 39 and 13 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 23, 9, 1, 35 and 5 molecules, respectively.

Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct


Introduction 13
Colorectal Cancer - Overview 14
Colorectal Cancer - Therapeutics Development 15
Colorectal Cancer - Therapeutics Assessment 83
Colorectal Cancer - Companies Involved in Therapeutics Development 115
Colorectal Cancer - Drug Profiles 257
Colorectal Cancer - Dormant Projects 2439
Colorectal Cancer - Discontinued Products 2462
Colorectal Cancer - Product Development Milestones 2468
Appendix 2479

List Of Tables


Number of Products under Development for Colorectal Cancer, H2 2018 83
Number of Products under Development by Companies, H2 2018 85
Number of Products under Development by Universities/Institutes, H2 2018 106
Products under Development by Companies, H2 2018 110
Products under Development by Universities/Institutes, H2 2018 146
Number of Products by Stage and Target, H2 2018 152
Number of Products by Stage and Mechanism of Action, H2 2018 166
Number of Products by Stage and Route of Administration, H2 2018 180
Number of Products by Stage and Molecule Type, H2 2018 182
Colorectal Cancer - Pipeline by 3-V Biosciences Inc, H2 2018 183
Colorectal Cancer - Pipeline by 3SBio Inc, H2 2018 183
Colorectal Cancer - Pipeline by 4SC AG, H2 2018 184
Colorectal Cancer - Pipeline by Aadi Bioscience Inc, H2 2018 184
Colorectal Cancer - Pipeline by AB Science SA, H2 2018 185
Colorectal Cancer - Pipeline by AbbVie Inc, H2 2018 185
Colorectal Cancer - Pipeline by AbGenomics International Inc, H2 2018 186
Colorectal Cancer - Pipeline by Abpro, H2 2018 186
Colorectal Cancer - Pipeline by Aclaris Therapeutics Inc, H2 2018 186
Colorectal Cancer - Pipeline by Adamed Sp z oo, H2 2018 187
Colorectal Cancer - Pipeline by ADC Therapeutics SA, H2 2018 187
Colorectal Cancer - Pipeline by Adhera Therapeutics, H2 2018 188
Colorectal Cancer - Pipeline by Aduro BioTech Inc, H2 2018 188
Colorectal Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2018 189
Colorectal Cancer - Pipeline by Advanced BioDesign, H2 2018 189
Colorectal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2018 189
Colorectal Cancer - Pipeline by Agency for Science, Technology and Research, H2 2018 190
Colorectal Cancer - Pipeline by Agenus Inc, H2 2018 190
Colorectal Cancer - Pipeline by AlfaSigma SpA, H2 2018 191
Colorectal Cancer - Pipeline by Alkermes Plc, H2 2018 191
Colorectal Cancer - Pipeline by Alligator Bioscience AB, H2 2018 192
Colorectal Cancer - Pipeline by Allinky Biopharma SL, H2 2018 192
Colorectal Cancer - Pipeline by Almac Discovery Ltd, H2 2018 192
Colorectal Cancer - Pipeline by Alpine Immune Sciences Inc, H2 2018 193
Colorectal Cancer - Pipeline by ALX Oncology Inc, H2 2018 193
Colorectal Cancer - Pipeline by Amarin Corp Plc, H2 2018 194
Colorectal Cancer - Pipeline by amcure GmbH, H2 2018 194
Colorectal Cancer - Pipeline by Amgen Inc, H2 2018 195
Colorectal Cancer - Pipeline by APEIRON Biologics AG, H2 2018 195
Colorectal Cancer - Pipeline by Apexigen Inc, H2 2018 195
Colorectal Cancer - Pipeline by Aphios Corp, H2 2018 196
Colorectal Cancer - Pipeline by Apogenix AG, H2 2018 196
Colorectal Cancer - Pipeline by Aposense Ltd, H2 2018 197
Colorectal Cancer - Pipeline by Arcus Biosciences Inc, H2 2018 197
Colorectal Cancer - Pipeline by Array BioPharma Inc, H2 2018 198
Colorectal Cancer - Pipeline by Arvinas Inc, H2 2018 198
Colorectal Cancer - Pipeline by Asana BioSciences LLC, H2 2018 199
Colorectal Cancer - Pipeline by Ascelia Pharma AB, H2 2018 199
Colorectal Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2018 199
Colorectal Cancer - Pipeline by Astellas Pharma Inc, H2 2018 200
Colorectal Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2018 200
Colorectal Cancer - Pipeline by AstraZeneca Plc, H2 2018 201
Colorectal Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2018 202
Colorectal Cancer - Pipeline by Aurobindo Pharma Ltd, H2 2018 202
Colorectal Cancer - Pipeline by B Cell Design SAS, H2 2018 203
Colorectal Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2018 203
Colorectal Cancer - Pipeline by Batu Biologics Inc, H2 2018 203
Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H2 2018 204
Colorectal Cancer - Pipeline by Bayer AG, H2 2018 205
Colorectal Cancer - Pipeline by BeiGene Ltd, H2 2018 205

List Of Figures


Number of Products under Development for Colorectal Cancer, H2 2018 83
Number of Products under Development by Companies, H2 2018 84
Number of Products under Development by Universities/Institutes, H2 2018 106
Number of Products by Top 10 Targets, H2 2018 151
Number of Products by Stage and Top 10 Targets, H2 2018 151
Number of Products by Top 10 Mechanism of Actions, H2 2018 165
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 165
Number of Products by Top 10 Routes of Administration, H2 2018 179
Number of Products by Stage and Top 10 Routes of Administration, H2 2018 179
Number of Products by Top 10 Molecule Types, H2 2018 181
Number of Products by Stage and Top 10 Molecule Types, H2 2018 181

Cervical Cancer - Pipeline Review, H2 2018 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Pipeline Review, H2 2018, provides an overview of the Cervical Cancer

View Report

Pancreatic Cancer - Pipeline Review, H2 2018 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H2 2018, provides an overview of the Pancreatic Cancer

View Report

Melanoma - Pipeline Review, H2 2018 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Melanoma - Pipeline Review, H2 2018, provides an overview of the Melanoma (Oncology) pipeline landscape. Melanoma

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports